Semaglutide significantly reduced fibrosis markers, inflammatory cytokines, and epithelial-mesenchymal transition in both cell and mouse models of intrauterine adhesions, suggesting a potential new application for this GLP-1 drug.
Reduced fibrosis + inflammation + EMTSemaglutide significantly decreased all three pathological processes driving intrauterine adhesion formation in both in vitro and in vivo models
What the researchers found
Semaglutide significantly reduced fibrosis markers (ACTA2, COL1A1, FN), inflammatory cytokines (TNF-α, IL-6, NF-κB), and epithelial-mesenchymal transition markers (vimentin, E-cadherin, N-cadherin) in both TGF-β1-induced endometrial cell and surgically-induced mouse models of intrauterine adhesions.
Why it matters
Intrauterine adhesions affect an estimated 20% of women who undergo uterine procedures. Finding that a widely available, well-characterized drug like semaglutide has anti-fibrotic and anti-inflammatory effects in the uterus could provide a new treatment option for a condition with limited therapeutic choices.
The numbers in context
Three semaglutide dose levels tested in animal models. Cell models showed dose-dependent effects on EMT markers after 48-hour treatment.
How the study worked
In vitro: human endometrial epithelial cells were stimulated with TGF-β1 and co-cultured with different semaglutide concentrations for 48h. In vivo: IUA was induced in mice by mechanical curettage plus inflammatory stimulation; three semaglutide doses were injected subcutaneously daily for 2 weeks. RT-qPCR, Western blotting, HE staining, Masson staining, and ELISA were used for analysis.
Who was studied
Human endometrial cells and animal intrauterine adhesion models
What this study cannot tell us
Preclinical study — no human clinical data for IUA treatment with semaglutide. The mouse IUA model doesn't perfectly replicate human disease. Daily SC injection for 2 weeks is a short treatment period. GLP-1 receptor expression in human endometrial tissue needs confirmation. Fertility outcomes were not assessed.
How to read the evidence
Preliminary evidence from cell culture and animal models. The results are consistent across both models, but clinical translation requires human studies.
When this study was published
Published in 2024, part of the growing research into non-metabolic applications of GLP-1 drugs.
The bigger picture
GLP-1 drugs keep surprising researchers with beneficial effects beyond blood sugar and weight. Anti-fibrotic properties have now been observed in the liver, kidneys, heart, and with this study, the uterus. This suggests GLP-1 receptor signaling may have a fundamental role in regulating fibrosis across multiple organs — a discovery with enormous therapeutic implications.
Questions still open
- Could semaglutide be used preventively after uterine procedures to reduce adhesion formation?
- Is the anti-fibrotic effect mediated through GLP-1 receptors in the endometrium or indirectly through systemic effects?
- Would semaglutide improve fertility outcomes in women with existing intrauterine adhesions?
Common questions
What are intrauterine adhesions and why are they a problem?
Could I use semaglutide to treat uterine adhesions?
Read the original research
Semaglutide May Ameliorate Fibrosis and Inhibit Epithelial-Mesenchymal Transition in Intrauterine Adhesion Models.
International journal of molecular sciences, 25(11)
Citation
Wu, Luming; Zhan, Yue; Wang, Yiqing. (2024). Semaglutide May Ameliorate Fibrosis and Inhibit Epithelial-Mesenchymal Transition in Intrauterine Adhesion Models.. International journal of molecular sciences, 25(11). https://doi.org/10.3390/ijms25116196